Chardan Healthcare Acquisition 2 Corp.

Chardan Healthcare Acquisition 2 Corp. is a blank-check company (SPAC) that raised $85M in its initial public offering on Apr 28, 2020, listing on NYSE American. It completed its business combination with Renovacor, Inc. on Sep 2, 2021; the combined company is Renovacor, Inc. (RCOR). Loeb & Loeb advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.

Renovacor is a preclinical-stage gene therapy company developing a pipeline of proprietary AAV-based gene therapies for diseases associated with BAG3 gene mutations. It is the target of a business combination with Chardan Healthcare Acquisition 2 Corp.

Status

Merger completed

IPO date

Apr 28, 2020

IPO size

$85M

IPO exchange

NYSE American

Target

Renovacor, Inc. (Old Renovacor)

Announced

Mar 23, 2021

Closed

Sep 2, 2021

Combined company

Renovacor, Inc. (RCOR)

SPAC counsel (IPO)

Loeb & Loeb

Underwriters' counsel (IPO)

Kirkland & Ellis